Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
administered, advantage, advertising, affirmed, affirming, artificial, auctioned, automatically, Banc, bankruptcy, Beacon, bidder, brand, Center, clarify, clearance, CLIA, CMS, Compel, Cosmetic, decommissioned, difficult, draft, En, enact, entity, EU, fall, FCPA, FDA, Foundation, geopolitical, grounded, guidance, hearing, high, holding, intelligence, Invitae, IVCT, IVDR, labeling, legislative, LH, literature, machine, Maximum, Michael, nationwide, noncompliance, NYSE, optimized, overseeing, oversight, pharmaceuitcal, pharmacogenetic, policy, premarket, proceed, processing, purporting, quality, refinance, refrain, Rehearing, reintroduced, reorganization, repayment, replace, robotic, scheduled, Senate, sound, sponte, sua, surveillance, symbol, systematic, Teri, uninterrupted, unmet, unmodified, unparalleled, unrelated, Verifying, vitro, voluntary, warning, Westpac, winning
Removed:
accelerate, accelerated, accessing, added, Additionally, Anderson, antibody, Ascension, attracting, backlog, bank, banking, biopsy, Bouffard, comparability, complement, dated, decline, deducted, deemed, default, defended, duration, Emergency, enhance, event, exceed, exemplary, FPCA, fraud, greater, independent, MCO, Michigan, modified, negatively, negotiated, NHP, pandemic, past, perception, prejudice, punitive, pursue, rely, retaining, Russia, Sheryl, spin, strong, temporarily, transitional, Ukraine, unavailable, unlawfully, variety, viability, Victoria, windfall
Financial report summary
?Risks
- General or macro-economic factors in the U.S. and globally may have a material adverse effect upon the Company, and significant fluctuations in global economic conditions and an increase in the costs of goods and services could negatively impact testing volumes, drug development services, cash collections, profitability, and the availability and cost of credit.
- Operations may be disrupted and adversely impacted by the effects of adverse weather, natural disasters, geopolitical events, public health crises, hostilities or acts of terrorism, acts of vandalism, disruption to supply chains, inaccessibility of natural resources, and other events beyond the Company's control.
- An inability to attract, retain, and develop experienced and qualified personnel, including key management personnel, and increased personnel costs, could adversely affect the Company’s business.
- Continued changes in healthcare reimbursement models and products (e.g., health insurance exchanges), changes in government payment and reimbursement systems, or changes in payer mix, including an increase in third-party benefits management and value-based payment models, could have a material adverse effect on the Company's revenues, profitability and cash flow.
- Changes in government regulation or in practices relating to the pharmaceutical, biotechnology, or medical device industries could decrease the need for certain services that BLS provides.
- Increased competition, including price competition, could have an adverse effect on the Company’s revenues and profitability.
- Failure to obtain and retain new customers, the loss of existing customers or material contracts, or a reduction in services or tests ordered or specimens submitted by existing customers, or the inability to retain existing and/or create new relationships with health systems could impact the Company’s ability to successfully grow its business.
- Changes or disruption in services, supplies, or transportation provided by third parties have impacted and could continue to impact or adversely affect the Company’s business.
- A failure to identify and successfully close and integrate strategic acquisition targets could have a material adverse effect on the Company's business objectives and its revenues and profitability.
- Unfavorable labor environments, union strikes, work stoppages, union or works council negotiations, or failure to comply with labor or employment laws could adversely affect the Company's operations and have a material adverse effect upon the Company's business.
- Continued and increased consolidation of pharmaceutical, biotechnology and medical device companies, health systems, physicians and other customers could adversely affect the Company's business.
- Risks Related to Financial Matters
- The Company bears financial risk for contracts that, including for reasons beyond the Company's control, may be underpriced, subject to cost overruns, delayed, or terminated or reduced in scope.
- A significant increase in the Company's days sales outstanding could have an adverse effect on the Company’s business, including its cash flow, by increasing its bad debt or decreasing its cash flow.
- BLS’s revenues depend on the pharmaceutical, biotechnology and medical device industries.
- The Company’s uses of financial instruments to limit its exposure to interest rate and currency exchange fluctuations could expose it to risks and financial losses that may adversely affect the Company’s financial condition, liquidity and results of operations.
- The Company’s level of indebtedness and debt service requirements could adversely affect the Company’s liquidity, results of operations and business.
- The Company's quarterly operating results may vary.
- Failure to maintain the security of customer-related information or compliance with security requirements could damage the Company’s reputation with customers, cause it to incur substantial additional costs and become subject to litigation and enforcement actions.
- Failure in the Company’s information technology systems or delays or failures in the development and implementation of new systems or updates or enhancements to existing systems could disrupt the Company’s operations or customer relationships.
- Cybersecurity incidents and unauthorized access to the Company's or its customers’ data could harm the Company’s reputation and adversely affect its business.
- The Company depends on third parties to provide services critical to the Company's business, and depends on them to comply with applicable laws and regulations. Additionally, any cybersecurity incidents affecting the information technology systems of third parties could have a material adverse effect on the Company's operations.
- Changes in payer regulations or policies, insurance regulations or approvals, or changes in laws, regulations, or policies in the U.S. or globally, including changes in their interpretation, may adversely affect the Company.
- Failure of the Company or its third-party service providers to comply with privacy and data security laws and regulations could result in fines, penalties and damage to the Company’s reputation with customers and have a material adverse effect upon the Company’s business.
- International operations may increase the Company’s exposure to liabilities under applicable anti-corruption laws.
- Failure to comply with the regulations of pharmaceutical and medical device regulatory agencies, such as the FDA, the Medicines and Healthcare Products Regulatory Agency in the United Kingdom, the European Medicines Agency, the National Medical Products Administration in China (NMPA), and the Pharmaceuticals and Medical Devices Agency in Japan, could result in fines, penalties, and sanctions against BLS and have a material adverse effect upon the Company.
- Animal populations may suffer diseases that can damage BLS's inventory, harm its reputation, or result in other liability.
- Failure to conduct animal research in compliance with animal welfare laws and regulations could result in sanctions and/or remedies against BLS and have a material adverse effect upon the Company.
- The failure to successfully obtain, maintain, and enforce intellectual property rights and defend against challenges to the Company’s intellectual property rights could adversely affect the Company.
- Changes in tax laws and regulations or the interpretation of such may have a significant impact on the financial position, results of operations, and cash flows of the Company.
- Contract services in the drug development industry create liability risks.